CHMFL-ABL-121

CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively[1].

Product Specifications

CAS Number

[2270879-07-5]

UNSPSC

12352005

Target

Apoptosis; Bcr-Abl

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/chmfl-abl-121.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=CC(C(F)(F)F)=C(CN2CCN(C)CC2)C=C1)CCSC3=CC(NN=C4/C=C/C5=CC=CC=N5)=C4C=C3

Molecular Formula

C30H31F3N6OS

Molecular Weight

580.67

References & Citations

[1]Liu X, et al. Discovery of (E) -N- (4- ((4-methylpiperazin-1-yl) methyl) -3- (trifluoromethyl) phenyl) -3- ((3- (2- (pyridin-2-yl) vinyl) -1H-indazol-6-yl) thio) propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur J Med Chem. 2018 Dec 5;160:61-81.